VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Histologically confirmed incurable relapsed or refractory solid tumor or non-Hodgkin's lymphoma that has been treated on MSKCC-01131 Must have completed participation in protocol MSKCC-01131 through visit 16 and have shown evidence of stable disease or complete or partial remission of tumor burden and no evidence of symptomatic deterioration No adverse event or toxicity which resulted in discontinuation of participation in protocol MSKCC-01131 If a patient experienced dose-limiting toxicity, then the patient must have demonstrated the ability to tolerate the same dose or a lower dose prior to entry in this study No known or suspected squamous cell carcinoma of the lung No prior or concurrent new neurological symptoms or CNS (brain or leptomeningeal) metastases during protocol MSKCC-01131 PATIENT CHARACTERISTICS: Age 25 and over Performance status ECOG 0-2 Life expectancy Not specified Hematopoietic WBC at least 3,500/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL No severe or uncontrolled hematologic condition Hepatic Bilirubin no greater than 1.5 times upper limit of normal (ULN) AST and ALT no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN PT, PTT, and INR normal Renal Creatinine no greater than ULN No 1+ or greater proteinuria No severe or uncontrolled renal condition Cardiovascular No severe or uncontrolled cardiovascular condition Pulmonary No severe or uncontrolled pulmonary condition Other No prior hypersensitivity reactions to any recombinant proteins (e.g., VEGF Trap) No severe or uncontrolled gastrointestinal, immunological, or musculoskeletal condition No severe or uncontrolled psychiatric condition or adverse social circumstance that would preclude study No other condition that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective double-barrier contraception during and for at least 3 months after study PRIOR CONCURRENT THERAPY: Biologic therapy No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF) No other concurrent immunotherapy Chemotherapy No concurrent standard chemotherapy Endocrine therapy No concurrent adrenal corticosteroids except low doses as replacement therapy in patients who have previously received suppressive doses or for adrenal insufficiency No concurrent systemic hormonal contraceptive agents Radiotherapy No concurrent radiotherapy Surgery Not specified Other At least 30 days since prior investigational therapy other than VEGF Trap No concurrent standard or other investigational anticancer agents No concurrent herbal supplements ("nutraceuticals") No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, aspirin, or other nonsteroidal anti-inflammatory drugs) except selective cyclo-oxygenase-2 (COX-2) inhibitors for analgesia No concurrent COX-2 inhibitors for tumor treatment or prophylaxis